Brief: GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
15/01/2026 13:32
Jan 15 (Reuters) - GT Biopharma Inc GTBP.O: GT BIOPHARMA ANNOUNCES IND SUBMISSION FOR GTB-5550 TRIKE®, A B7-H3-TARGETED NATURAL KILLER (NK) CELL ENGAGER FOR B7-H3 EXPRESSING SOLID TUMOR CANCERS Source text: ID:nGNX2GmyRQ Further company coverage: GTBP.O ((Reuters.Briefs@thomsonreuters.com;))